九强生物
(300406)
| 流通市值：61.70亿 | | | 总市值：85.54亿 |
| 流通股本：4.24亿 | | | 总股本：5.88亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,658,931,975.39 | 1,237,396,355.82 | 821,722,324.81 | 393,894,885.38 |
| 营业收入 | 1,658,931,975.39 | 1,237,396,355.82 | 821,722,324.81 | 393,894,885.38 |
| 二、营业总成本 | 1,056,135,883.84 | 793,399,425.93 | 518,454,199.71 | 252,157,863.84 |
| 营业成本 | 356,698,572.97 | 274,578,957.58 | 186,299,645.98 | 91,143,372.7 |
| 税金及附加 | 15,445,248.25 | 11,938,565.26 | 7,278,214.32 | 3,668,591.43 |
| 销售费用 | 314,172,887.12 | 240,932,669.56 | 147,674,341.51 | 69,720,757.44 |
| 管理费用 | 143,501,619.57 | 105,307,615.95 | 69,914,142.33 | 34,075,533.29 |
| 研发费用 | 188,526,524.96 | 129,511,221.98 | 86,944,037.45 | 42,889,988.58 |
| 财务费用 | 37,791,030.97 | 31,130,395.6 | 20,343,818.12 | 10,659,620.4 |
| 其中:利息费用 | 47,605,385.02 | 35,441,089.73 | 23,380,926.38 | 11,796,810.8 |
| 其中:利息收入 | 10,210,078.75 | 4,752,693.99 | 3,414,971.12 | 1,563,513.65 |
| 加:投资收益 | 9,613,993.45 | 1,725,900.91 | 1,398,418.93 | 1,115,166.92 |
| 资产处置收益 | -2,112,317.8 | -2,201,612.67 | -1,247,038.46 | -290,627.64 |
| 资产减值损失(新) | -5,185,768.92 | 0 | 0 | 0 |
| 信用减值损失(新) | -629,687.38 | -6,781,439.51 | -6,782,017.91 | 90,000 |
| 其他收益 | 19,568,251.39 | 6,937,950.17 | 6,007,446 | 1,728,678.63 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 624,050,562.29 | 443,677,728.79 | 302,644,933.66 | 144,380,239.45 |
| 加:营业外收入 | 1,478,944.47 | 68,893.27 | 22,857.28 | 15,714.3 |
| 减:营业外支出 | 4,840,447.4 | 2,213,723.09 | 2,092,835.03 | 1,988,002.82 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 620,689,059.36 | 441,532,898.97 | 300,574,955.91 | 142,407,950.93 |
| 减:所得税费用 | 89,526,853.36 | 69,130,619.97 | 50,987,663.65 | 22,188,466.89 |
| 六、净利润 | 531,162,206 | 372,402,279 | 249,587,292.26 | 120,219,484.04 |
| 持续经营净利润 | 531,162,206 | 372,402,279 | 249,587,292.26 | 120,219,484.04 |
| 归属于母公司股东的净利润 | 532,635,347.43 | 373,384,271.63 | 250,373,606.97 | 120,648,449.77 |
| 少数股东损益 | -1,473,141.43 | -981,992.63 | -786,314.71 | -428,965.73 |
| (一)基本每股收益 | 0.92 | 0.63 | 0.43 | 0.21 |
| (二)稀释每股收益 | 0.9 | 0.63 | 0.43 | 0.21 |
| 八、其他综合收益 | 280,702.14 | -163,841.94 | 110,421.36 | 37,868.49 |
| 归属于母公司股东的其他综合收益 | 220,443.8 | -135,197.27 | 85,240.64 | 27,198.35 |
| 九、综合收益总额 | 531,442,908.14 | 372,238,437.06 | 249,697,713.62 | 120,257,352.53 |
| 归属于母公司股东的综合收益总额 | 532,855,791.23 | 373,249,074.36 | 250,458,847.61 | 120,675,648.12 |
| 归属于少数股东的综合收益总额 | -1,412,883.09 | -1,010,637.3 | -761,133.99 | -418,295.59 |
| 公告日期 | 2025-03-29 | 2024-10-29 | 2024-08-23 | 2024-04-29 |
| 审计意见(境内) | 标准无保留意见 | | | |